Summer Sale
50% off Premium Yearly
Opinions JoAnne Feeney
BioNTechBNTXTOP PICKMay 14, 2021
JoAnne FeeneyStock price when the opinion was issued
As of Aug 24, 2026. Market Open.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium contentPremium contentThis $24 billion German based pharma company has received approvals to continue advancement into a new uterine cancer treatment. It trades at 8x trailing earnings, 1.1x book and supports a 23% ROE. Cash reserves are growing, while stock is bought back. We recommend placing a stop-loss at $78, looking to achieve $137 -- upside potential of 31%. Yield 0%
(Analysts’ price target is $137.07)Premium contentPremium contentThe $28 billion biotech just received FDA approval of their updated COVID vaccine. It trades at 6x earnings, 1.3x book and supports a 23% ROE. We like that cash reserves are growing, while shares are bought back and debt is retired. We recommend placing a stop-loss at $100, looking to achieve $161 -- upside potential of 40%. Yield 0%
(Analysts’ price target is $161.34)
Provides the key insight into mRNA that underlies the Covid vaccine. The mRNA technology can be developed into therapies that are targeted and safe. They are working on a flu vaccine as well as a cancer vaccine. Their pipeline is vast and the coronavirus vaccine is giving a huge cash hoard to pay for R&D. (Analysts’ price target is $185.00)